Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 718Lung Neoplasms 310Small Cell Lung Carcinoma 111Neoplasms 42Adenocarcinoma of Lung 40Neoplasm Metastasis 35Parkinson Disease 4, Autosomal Dominant Lewy Body 22Brain Neoplasms 21Carcinoma 19Breast Neoplasms 18Lung Diseases 15NSCLC 14Mesothelioma, Malignant 14Thoracic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Prostatic Neoplasms 11Pleural Effusion, Malignant 10Non-Squamous Non-Small Cell Lung Cancer 10Mesothelioma 10Cachexia 10Respiratory Tract Neoplasms 9Pain 9Bronchial Neoplasms 9Respiratory Tract Diseases 8Carcinoma, Squamous Cell 8Carcinoma, Bronchogenic 8Adenocarcinoma 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

Pemetrexed 2Gemcitabine 2Cisplatin 2Carboplatin 2CP protocol 2durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Non Small Cell Lung Carcinoma NSCLC × Thoracic × Clear all
NCT02542293 2026-05-01

NEPTUNE

AstraZeneca

Phase 3 Active not recruiting
953 enrolled 29 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

AstraZeneca

Phase 3 Active not recruiting
669 enrolled 54 charts
Thoracic

Non Small Cell Lung Carcinoma NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡